Neuro-oncology: The long and winding road--gene therapy for glioma
- PMID: 24061435
- PMCID: PMC3928109
- DOI: 10.1038/nrneurol.2013.198
Neuro-oncology: The long and winding road--gene therapy for glioma
Abstract
Gene therapy approaches for glioblastoma multiforme (GBM) have been under investigation in clinical trials since the 1990s, but the results to date have been disappointing. A recently published phase III trial of adenovirus-based gene therapy for GBM has demonstrated modest—but possibly clinically relevant—improvements in patient survival.
Conflict of interest statement
Competing interests
The authors declare no competing interests.
Comment on
-
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial.Lancet Oncol. 2013 Aug;14(9):823-33. doi: 10.1016/S1470-2045(13)70274-2. Epub 2013 Jul 12. Lancet Oncol. 2013. PMID: 23850491 Clinical Trial.
References
-
- Rainov NG. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11:2389–2401. - PubMed
-
- Westphal M, et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:823–833. - PubMed
-
- Sandmair AM, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther. 2000;11:2197–2205. - PubMed
-
- Immonen A, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther. 2004;10:967–972. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical